（编辑 王雪儿） 证券日报网讯 1月30日，贤丰控股发布公告称，公司预计2025年1月1日至2025年12月31日归属于上市公 司股东的净利润为1，660万元至2，480万元，比上年同期增长114.69%至121.95%。 ...

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting a profit range of 16.6 million to 24.8 million yuan, representing a year-on-year growth of 114.69% to 121.95% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 16.6 million to 24.8 million yuan for 2025, marking a substantial turnaround from previous losses [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -20.8 million and -14 million yuan [1] - Non-recurring gains are estimated at approximately 44 million yuan, primarily from the disposal of factory assets [1] Business Operations - The company has achieved stable revenue growth, primarily driven by the expansion of its copper-clad laminate business, which has laid a solid foundation for overall performance [1] - The improvement in the company's operating fundamentals has contributed to the turnaround in net profit, alongside positive contributions from non-recurring gains [1] - The reduction in losses from the previous year is attributed to the growth in the copper-clad laminate business, which has enhanced the profitability of the main operations [1]

Financial Performance - The company expects a net profit for 2025, indicating a turnaround from previous losses, with an estimated profit range of 1,660 to 2,480 million CNY, representing a year-on-year increase of 114.69% to 121.95%[3][4] - The net profit attributable to shareholders after deducting non-recurring losses is projected to be between -2,080 and -1,400 million CNY, showing a year-on-year improvement of 84.16% to 89.34%[4] - The basic earnings per share are estimated to be between 0.0162 and 0.0242 CNY, compared to a loss of 0.1045 CNY in the previous year[4] Revenue and Business Growth - The company's revenue growth is primarily driven by the expansion of its copper-clad laminate business, which has laid a solid foundation for overall performance improvement[6] - The overall business fundamentals have shown continuous improvement, contributing positively to the company's profitability[6] Non-Recurring Items and Impairments - Non-recurring gains are expected to amount to approximately 44 million CNY, mainly from the disposal of factory assets[7] - The company has not recorded significant goodwill impairment in the current period, contrasting with substantial impairments in the previous year[7] - The company has conducted a preliminary assessment of asset impairments, which will be finalized by qualified evaluation and auditing institutions[8] Financial Data and Audit - The financial data presented is preliminary and has not been reviewed by external auditors, with final figures to be disclosed in the 2025 annual report[5][8] - Investors are advised to be cautious regarding investment risks as the financial data is subject to change pending final audits[8]

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

Market Overview - The three major A-share indices opened lower on January 27, with the Shanghai Composite Index closing at 4139.9 points, up 0.18% [2] - The ChiNext Index rose by 0.71% to 3342.6 points, while the Sci-Tech 50 Index increased by 1.51% to 1555.98 points [2] Trading Activity - A total of 1928 stocks rose, while 3450 stocks fell, with 91 stocks remaining flat [3] - The total trading volume was 28.949 billion yuan, a decrease of 3.533 billion yuan from the previous trading day [3] Sector Performance - Semiconductor stocks saw significant gains, with over 20 stocks hitting the daily limit or rising more than 10% [5] - Gold stocks also performed well, with several stocks reaching the daily limit or increasing by over 10% [5] - Coal and basic metal sectors experienced notable declines, with major coal stocks dropping over 4% [6] Market Sentiment and Predictions - Financial analysts suggest that the A-share market may continue to experience fluctuations in the short term due to increased overseas uncertainties and pressure at previous high levels [7] - The current market is viewed as a short-term adjustment risk, with expectations for continued upward movement in the medium term [7] - Long-term perspectives indicate that the current market trend is still in its mid-stage, with potential for a "slow bull" market to continue [8][9] Investment Recommendations - Analysts recommend focusing on sectors such as technology, particularly AI and robotics, as well as industries benefiting from price increases like chemicals and non-ferrous metals [8][9] - Short-term investment opportunities are suggested in power equipment and photovoltaic sectors, which are supported by market demand and policies [10]

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

Core Viewpoint - The company, Xianfeng Holdings, announced the need to replace its independent director, Mr. Deng Yanchang, due to the expiration of his six-year term as per regulations [2] Group 1: Independent Director Tenure - Mr. Deng Yanchang has served as an independent director since January 23, 2020, and his term is about to reach the six-year limit [2] - According to the "Management Measures for Independent Directors of Listed Companies," independent directors can serve a maximum of six consecutive years [2] Group 2: Replacement Process - The company is currently in the process of nominating candidates for the independent director position and related preparations [2] - The election for the new independent director will be postponed to ensure continuity and stability in the board's operations [2] Group 3: Governance and Stability - Until the new independent director is elected, Mr. Deng will continue to fulfill his responsibilities in accordance with the Company Law and relevant regulations [2] - The delay in the replacement of the independent director will not affect the normal functioning of the company's board [2]

特此公告。 贤丰控股股份有限公司 董事会 2026 年 1 月 22 日 关于延期更换选举独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 贤丰控股股份有限公司（以下简称"公司"）现任独立董事邓延昌先生自 2020 年 1 月 23 日起担任公司独立董事，连任期限即将满六年。根据《上市公司 独立董事管理办法》关于"独立董事每届任期与上市公司其他董事任期相同，任 期届满，可以连选连任，但是连续任职不得超过六年"的规定，公司需要更换选 举独立董事。 目前，公司正在依法依规开展独立董事候选人提名及相关筹备工作，鉴于公 司独立董事候选人提名等工作尚未完成，为确保公司董事会工作的连续性和稳定 性，经审慎研究决定，本次更换选举独立董事工作将适当延期。在新任独立董事 选举完成前，原独立董事邓延昌先生将继续依照《公司法》《公司章程》及相关 监管规定履行独立董事职责，确保公司治理结构平稳运行。 公司独立董事的延期更换选举不会影响公司董事会的正常运行。公司将在相 关董事提名人选确定后，尽快完成独立董事的更换选举工作并及时履行相应信息 披露义务。 证券代码：00214 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

Group 1 - The A-share market saw active trading in PCB concept stocks, with notable gains in several companies [1] - Tian Tong Co., Ltd. and Jin An Guo Ji both reached the daily limit up, while Xian Feng Holdings also showed significant growth [1] - Other companies like Da Zhu CNC and Si Hui Fu Shi experienced increases of over 9%, indicating strong market interest [1] Group 2 - Tian Tong Co., Ltd. had a price increase of 10.03%, with a total market capitalization of 16.2 billion [2] - Jin An Guo Ji rose by 10.01%, bringing its market value to 17 billion, and has a year-to-date increase of 39.44% [2] - Xian Feng Holdings increased by 9.97%, with a market cap of 4.328 billion and a year-to-date growth of 12.33% [2] - Da Zhu CNC saw a rise of 9.37%, with a market capitalization of 75.1 billion and a year-to-date increase of 48.57% [2] - Si Hui Fu Shi's stock price increased by 9.14%, with a market cap of 7.305 billion and a year-to-date growth of 19.20% [2] - Baiyin Youse and Zhongjing Electronics both experienced gains of over 6%, with market caps of 67.8 billion and 7.952 billion respectively [2] - Guanghe Technology and Chongda Technology saw increases of over 5%, with market caps of 43 billion and 18.8 billion respectively [2]